Creoptix AG closes CHF8m financing round

The financing round was led by Swisscanto Invest by Zürcher Kantonalbank and joined by Waters Corporation as well as existing private investors. Upon the first closing, Robert Schier of Swisscanto Invest joined the board of directors. The Series C financing round brings the total amount raised by Creoptix AG to more than CHF15m. Creoptix said, it will use the proceeds to strengthen its commercial operations in Europe and the US.

Creoptix AG (Wädenswil, near Zurich, Switzerland) has developed the Creoptix WAVE systems to study molecular interactions of ligands such as small molecules, peptides, proteins etc with drug targets in crude samples like undiluted serum or plasma.  The company’s label free waveguide interferometry technology is superior in sensitivity compared to Surface Plasmon Resonance (SPR), with a crude sample robustness normally only achieved with plate-based assays. The technology is facilitating new analytical applications such as membrane protein analysis in drug discovery and real-time kinetic interaction studies in body fluids for biomarker discovery and the development of new biologics .

Eduard M. Brunner, Chairman of Creoptix, said: "Creoptix, with its next-generation WAVE systems, has significant potential to make a real impact on the bioanalytical instruments market. We are pleased to welcome Swisscanto Invest as a new investor that will help drive our innovation in the years ahead."